Please ensure Javascript is enabled for purposes of website accessibility
Search
Accessibility Menu
Neumora Therapeutics Stock Quote

Neumora Therapeutics (NASDAQ: NMRA)

$9.19
(-5.9%)
-$0.58
Price as of May 10, 2024, 4:00 p.m. ET

Neumora Therapeutics Return vs. S&P

1 Year 5 Year 5 Year Annualized Since IPO
NMRA -43%
S&P +26.44% +81.25% +12.62% +17%

Neumora Therapeutics Company Info

Neumora Therapeutics, Inc. is a clinical-stage biotechnology company. It offers a precision medicine approach for brain diseases through the integration of data science and neuroscience. The firm focuses on advancing medicines for therapeutically relevant targets implicated in CNS diseases, targeting novel mechanisms of action with best-in-class pharmacology. The company was founded by Paul L. Berns, Carol Suh and Mike Poole in November 2019 and is headquartered in Watertown, MA.

News & Analysis

Valuation

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.